-
公开(公告)号:US20220175748A1
公开(公告)日:2022-06-09
申请号:US17436270
申请日:2020-02-19
发明人: Michael P. Eaton
IPC分类号: A61K31/4439 , C07K16/44 , A61P7/02 , A61K39/395
摘要: The invention relates to novel compositions managing or inhibiting blood clotting and related uses.
-
公开(公告)号:US11351178B2
公开(公告)日:2022-06-07
申请号:US16491827
申请日:2018-04-12
申请人: ITALFARMACO S.P.A.
发明人: Barbara Vergani , Gianluca Caprini , Gianluca Fossati , Maria Lattanzio , Mattia Marchini , Gianfranco Pavich , Marcello Pezzuto , Chiara Ripamonti , Giovanni Sandrone , Christian Steinkühler , Andrea Stevenazzi
IPC分类号: A61K31/4365 , A61K31/427 , A61K31/506 , A61K45/06 , A61K31/496 , A61K31/4196 , A61K31/5377 , A61K31/41 , A61K31/55 , A61K31/497 , A61K31/4245 , A61K31/437 , A61K31/433 , A61K31/4725 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/454 , C07D249/12 , C07D249/08 , C07D401/06 , C07D401/04 , C07D271/06 , C07D271/10 , C07D405/04 , C07D405/14 , C07D417/06 , C07D417/04 , C07D471/04 , C07D257/04 , C07D409/14 , C07D409/04 , C07D403/04 , C07D405/06 , C07D495/04 , C07D413/04 , A61P35/00 , A61P29/00 , A61P27/00 , A61P25/00 , C07D271/113 , C07D285/125 , C07D491/107
摘要: The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.
-
公开(公告)号:US20220168285A1
公开(公告)日:2022-06-02
申请号:US17671207
申请日:2022-02-14
申请人: XSPRAY PHARMA AB
IPC分类号: A61K31/44 , A61K31/4439 , A61K9/14 , A61K9/16 , A61K31/5377 , A61K47/38 , A61K9/00 , A61K9/51 , A61K31/444 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K47/32 , A61K31/517
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US11345672B2
公开(公告)日:2022-05-31
申请号:US16688469
申请日:2019-11-19
申请人: Valo Health, Inc.
发明人: Jennifer Lee , Nicholas Barczak , Jaime A. Escobedo , Chiara Conti , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Xiaozhang Zheng
IPC分类号: C07D263/58 , A61P35/00 , A61K31/403 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/435 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/4709 , A61K31/4985 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07C53/06 , C07D209/40 , C07D209/54 , C07D221/20 , C07D235/30 , C07D277/82 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D473/00 , C07D487/04 , C07D491/056 , C07D491/107 , C07D498/04
摘要: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
-
公开(公告)号:US11344533B2
公开(公告)日:2022-05-31
申请号:US16874073
申请日:2020-05-14
IPC分类号: A61K31/4155 , C07D403/04 , A61K45/06 , C07D401/14 , A61K31/4439 , C07D401/04 , C07D405/14 , A61K9/00 , A61K9/06 , A61K9/20 , A61K9/48 , A61K9/08 , C07D493/10
摘要: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
-
公开(公告)号:US20220160664A1
公开(公告)日:2022-05-26
申请号:US17429153
申请日:2020-02-07
发明人: Will MCLEAN , Megan S. HARRISON , Bradley TAIT
IPC分类号: A61K31/19 , A61K31/5377 , A61K31/444 , A61K31/4545 , A61K38/17 , A61K31/4725 , A61K31/443 , A61K31/4439 , A61K31/496 , A61K31/4409 , A61K31/195 , A61K31/495 , A61K31/4465 , A61K31/135 , A61K31/15 , A61K31/7064 , A61K31/7076 , A61K31/5517 , A61K31/506 , A61P27/16
摘要: Provided are compositions and methods comprising a TAZ activator and a Wnt agonist for increasing proliferation of cochlear supporting cells or vestibular supporting cells, and related methods of treating inner ear hearing or balance disorders.
-
公开(公告)号:US20220160652A1
公开(公告)日:2022-05-26
申请号:US17437087
申请日:2020-03-11
申请人: KAYDENCE PHARMA AS
发明人: Rick VAN GORP
IPC分类号: A61K31/122 , A61K31/422 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K45/06 , A61P7/02
摘要: A method of treating or preventing a condition characterized by unacceptable blood clotting and/or an increased risk thereof, the method including administering to a subject in need thereof a combination of vitamin K2 and at least one anticoagulant, the at least one anticoagulant having a first anticoagulant configured to inhibit free Factor Xa and/or Factor Xa bound in a prothrombinase complex of the subject.
-
公开(公告)号:US11338014B2
公开(公告)日:2022-05-24
申请号:US16828895
申请日:2020-03-24
发明人: Sumayah Jamal
IPC分类号: A61K38/16 , A61K31/506 , A61K31/44 , A61K31/437 , A61K38/05 , A61K38/12 , A61K31/4025 , A61K31/454 , A61P35/00 , A61K31/403 , A61K31/455 , A61K45/06 , A61P35/04 , A61K31/4439 , A61K9/51 , C07K16/26 , G01N33/574 , C07K16/28
摘要: The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.
-
公开(公告)号:US20220152116A1
公开(公告)日:2022-05-19
申请号:US17649512
申请日:2022-01-31
发明人: Aleksandr M. Aliper , Aleksandrs Zavoronkovs , Ivan Ozerov , Marine E. Bozdaganyan , Artem V. Artemov
IPC分类号: A61K35/28 , A61K31/195 , A61K38/17 , A61K31/4709 , A61K31/519 , A61K31/506 , A61K31/4439 , A61K31/353 , A61K31/453 , A61K31/416 , A61K31/4412 , A61K31/192 , A61K31/436 , A61K31/12 , A61K45/06 , A61K31/4745 , A61K31/44 , A61K38/16 , A61K31/585 , A61K31/352 , A61K31/196 , A61K35/36 , A61K31/26
摘要: A method of treating senescence in a subject can include applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject, wherein the senoremediation drug treatment protocol is derived from a computational transcriptome analysis of the tissue or organ of the subject. The method can include applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject. The method can include introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ. The method can include carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ.
-
公开(公告)号:US20220152007A1
公开(公告)日:2022-05-19
申请号:US17554737
申请日:2021-12-17
发明人: Ken FALLIN , Kaity RENAUD , Peter MIONE , Neal MUNI , Anisa GANDHI
摘要: Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have desirable viscosities and enhanced stability.
-
-
-
-
-
-
-
-
-